Covid-19 roundup: Buoyed by soar­ing shares, No­vavax inks a $167M deal to buy Covid-19 vac­cine-mak­ing fa­cil­i­ty; France cools on hy­drox­y­chloro­quine

The pan­dem­ic has of­fered the best news No­vavax has had in years. Its stock price is trad­ing at 7x the pre-pan­ic lev­els with a Covid-19 vac­cine in the mix, as in­vestors buy any­thing that moves in that field, and they’re flush to carve out their own path­way on the man­u­fac­tur­ing front.

Wednes­day morn­ing No­vavax re­port­ed that they are spend­ing $167 mil­lion on the Czech-based Pra­ha Vac­cines, bag­ging a man­u­fac­tur­ing fa­cil­i­ty along the way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER